€61.24
0.76% today
L&S, Jul 04, 10:54 pm CET
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Gilead Sciences Stock price

$66.59
+3.16 4.98% 1M
-16.89 20.23% 6M
-14.42 17.80% YTD
-10.13 13.20% 1Y
-2.71 3.91% 3Y
-2.41 3.49% 5Y
-21.31 24.24% 10Y
Nasdaq, Closing price Wed, Jul 03 2024
-1.81 2.65%
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Key metrics

Market capitalization $82.96b
Enterprise Value $102.01b
PER (TTM) P/E ratio 185.64
EV/FCF (TTM) EV/FCF 12.91
EV/Sales (TTM) EV/Sales 3.72
P/S ratio (TTM) P/S ratio 3.03
P/B ratio (TTM) P/B ratio 4.73
Dividend yield 4.51%
Last dividend (FY23) $3.00
Revenue growth (TTM) Revenue growth 2.13%
Revenue (TTM) Revenue $27.42b
EBIT (operating result TTM) EBIT $9.33b
Free Cash Flow (TTM) Free Cash Flow $7.90b
Cash position $6.06b
EPS (TTM) EPS $0.36
P/E forward 187.70
P/S forward 3.01
EV/Sales forward 3.70
Short interest 1.51%
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Analyst Opinions

32 Analysts have issued a Gilead Sciences forecast:

15x Buy
47%
17x Hold
53%

Analyst Opinions

32 Analysts have issued a Gilead Sciences forecast:

Buy
47%
Hold
53%

Financial data from Gilead Sciences

Mar '24
+/-
%
Net Profit 484 484
91% 91%
2%
Depreciation and Amortization 2,743 2,743
24% 24%
10%
Stock Compensation 788 788
17% 17%
3%
Operating Cash Flow 8,480 8,480
6% 6%
31%
Investments 581 581
2% 2%
2%
Dividend Paid 3,830 3,830
3% 3%
14%
Free Cash Flow 7,899 7,899
6% 6%
29%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Seeking Alpha
3 days ago
Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential rate of return. In comparison to Morningstar's 10 Best Value Stocks with 10 Best Dividend Stocks, Bristol-Myers stands out as undervalued with a high po...
Positive
The Motley Fool
3 days ago
AbbVie is a Dividend King poised for growth. Gilead Sciences is a stable, low-risk candidate for investors.
Positive
Seeking Alpha
10 days ago
Gilead Sciences reported positive Phase 3 data for lenacapavir, a biannual HIV PrEP therapy, leading to a 12% stock boost. Q1 earnings showed growth in HIV product sales, with Trodelvy's notable 39% increase, and total revenue beating estimates by $350 million. Financially, Gilead has a current ratio of just over one, indicating the ability to meet short-term obligations, despite high leverage ...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 18,000
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today